Form 4/A for MNKD MANNKIND CORP
Accepted 2022-05-25 00:00:00 ET · period of report 2022-05-18 · accession 0001209191-22-031996 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-05-25 | 2022-05-18 | MNKD | Galindo Alejandro | EVP Endocrine Business Unit | I - Discretionary | $3.19 | +4,789 | 776.7K | +0.6% | +$15.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $.01 Par Value | 2022-05-18 | I | A | 4,789 | $3.19 | 776,690 | D | — | — |